The choice of postremission therapy for acute myeloid leukemia (AML) patients is now based on the blasts' cytogenetic and molecular profile. However, the potential benefit of autologous hematopoietic stem cell transplantation (auto-HSCT) according to the NPM1/FLT3-ITD status has been poorly studied in AML patients with a normal karyotype (NK). Therefore, we evaluated the NPM1/FLT3-ITD molecular status in 135 NK-AML patients treated by allogeneic HSCT (allo-HSCT), auto-HSCT, or chemotherapy as consolidation therapy within the GOELAMS LAM-2001 trial. In univariate analyzes, 4-year leukemia-free survival (LFS) and overall survival (OS) were significantly higher for NPM1+/FLT3-ITD- patients compared with patients presenting another molecular profile (61 vs. 43% and 72 vs. 48%, P = 0.02 and P = 0.01, respectively). In the NPM1+/FLT3-ITD- subgroup, there was no benefit for allo-HSCT or auto-HSCT vs. chemotherapy (4-year LFS: 71, 56, and 60%; 4-year OS: 73, 71, and 60%, respectively; P = NS). For patients with other NPM1/FLT3-ITD molecular profiles, allo-HSCT was found to be the best consolidation therapy, whereas auto-HSCT was associated with a better outcome when compared with chemotherapy (allo-HSCT-, auto-HSCT-, and chemotherapy-related 4-year LFS: 68, 44, and 36%, P = 0.004; 4-year OS: 68, 52, and 29%, respectively, P = 0.02). Our study indicates that allo-HSCT and auto-HSCT provide similar outcomes compared with chemotherapy as consolidation for NPM1+/FLT3-ITD- NK-AML patients. For NK-AML patients with an adverse molecular profile, auto-HSCT could represent an alternative therapeutic approach when no human leukocyte antigen-matched allogeneic donor is available.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.23311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Prevalence and Prognostic Impact of Wilms Tumor 1 Exon 7 Mutation Status with Combinations of FLT3-ITD and NPM1 Mutations as Potential Molecular Biomarkers in Acute Myeloid Leukemia Patients with Normal Cytogenetics.
Asian Pac J Cancer Prev
October 2024
Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, University of Kerala, India.
Article Synopsis
- This study investigates the effects of specific genetic mutations (FLT3-ITD, NPM1, WT1) on the outcomes of patients with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML), finding notable survival differences based on NPM1 mutation status.
- Out of 150 patients analyzed, 12.6% had WT1 mutations, and relationships were identified between mutation presence and certain clinical factors, like LDH and hemoglobin levels; however, correlations with overall survival were not consistently significant.
- The results indicate that assessing NPM1 and FLT3-ITD mutations at diagnosis can help predict patient prognosis in AML; further research with larger groups could provide deeper insights
Background: There are no studies assessing the evolution and patterns of genetic studies performed at diagnosis in acute myeloid leukemia (AML) patients. Such studies could help to identify potential gaps in our present diagnostic practices, especially in the context of increasingly complex procedures and classifications.
Methods: The REALMOL study (NCT05541224) evaluated the evolution, patterns, and clinical impact of performing main genetic and molecular studies performed at diagnosis in 7285 adult AML patients included in the PETHEMA AML registry (NCT02607059) between 2000 and 2021.
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.
EJHaem
February 2024
Service d'Hématologie Biologique CHU de Dijon Dijon France.
Risk stratification and treatment response evaluation are key features in acute myeloid leukemia (AML) management. Immunophenotypic and molecular approaches all rely on the detection of persisting leukemic cells by measurable residual disease techniques. A new approach is proposed here by assessing medullary myeloid maturation by flow cytometry through a myeloid progenitor ratio (MPR).
View Article and Find Full Text PDFPrognostic impact of FLT3-ITD mutation on NPM1 acute myeloid leukaemia patients and related molecular mechanisms.
Br J Haematol
October 2023
National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
The prognosis of acute myeloid leukaemia (AML) patients carrying NPM1 mutations is significantly worse when accompanied by FLT3-ITD mutations. However, accurate quantitative detection of FLT3-ITD mutations remains challenging. To identify a novel biomarker in NPM1 FLT3-ITD AML patients for more accurate stratification, we analysed the differential gene expression between the NPM1 FLT3-ITD and NPM1 FLT3-ITD groups in five public AML datasets and identified a biomarker by taking the intersection of differentially expressed genes.
View Article and Find Full Text PDFCytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
Hematol Oncol Stem Cell Ther
May 2023
Division of Haematology, Department of Pathology, Faculty of Health Sciences, University of Cape Town and NHLS, Groote Schuur Hospital, South Africa.
Background And Objectives: The heterogeneous molecular landscape of cytogenetically normal acute myeloid leukemia (CN-AML) renders it an ongoing therapeutic challenge. The European LeukemiaNet (ELN) 2017 guidelines attempted to address this by guiding post-remission therapy according to six prognostically informative mutations. However, its applicability in a South African setting remains unclear due to limited local data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!